
Social Withdrawal in Aging Tied to Shifts in Brain Networks
'Our study suggests that age-related changes in the functional wiring of the brain may impair certain abilities needed to maintain social relationships,' the study's lead study author Yuet Ruh Dan, Duke-National University of Singapore Medical School, told Medscape Medical News .
The findings were published online on May 28 in PLOS One .
Sociability Critical to Health
Sociability, which is the capacity to communicate effectively, be socially assertive, and to manage emotions, is 'critical' for maintaining and promoting health, especially as we age, said Dan.
Research has linked sociability to increased functional connectivity in and between intrinsic brain networks. Overall, the default mode network (DMN), ventral attention network, and limbic structures have been the most strongly correlated with sociability.
The aging process also involves changes in intrinsic brain networks. Studies have shown that aging results in lower within-network connectivity, as well as greater between-network connectivity.
For example, Dan noted that connectivity between the frontoparietal and DMNs decreases with age change that has been linked to poorer self-esteem and memory. Meanwhile, connectivity between the limbic and insular regions increases with age and has been shown to activate in situations involving social exclusion, she added.
'Intuitively, poorer self-esteem and an increased sensitivity to exclusion may be linked to a decreased ability to communicate with others and regulate our emotions,' she said.
This study is among the first — if not thefirst — to directly examine the relationship between age-related changes in functional connectivity and sociability, Dan added.
The study included 196 healthy participants aged 20-77 years (mean age, approximately 38 years), with 34.2% identifying as female, drawn from the Leipzig Study for Mind-Body-Emotion Interactions dataset. For the analysis, researchers grouped participants into 5-year age brackets (20-25, 25-30, etc.), Dan said.
In addition, the researchers obtained resting-state functional MRI data. Participants completed the sociability subscale of the Trait Emotional Intelligence Questionnaire Short Form.
This six-question subscale measures social awareness, emotional management, communication effectiveness, and participation in social situations. The questionnaire is scored on a 7-point Likert scale ranging from 1 (completely disagree) to 7 (completely agree), with higher scores indicating higher levels of sociability.
Researchers also collected data using the NEO Five-Factor Inventory (NEO-FFI), which measures neuroticism, extraversion, openness to new experiences, agreeableness, and conscientiousness. They found a strong positive correlation between sociability and extraversion ( P < .001), highlighting a significant link between the two traits.
Researchers conducted network-based analyses to identify patterns of resting-state functional connectivity, grouping the data into an age-positive network (APN), which showed a positive correlation with age, and an age-negative network (ANN), which showed a negative correlation.
'Essentially, we found that with increased age, there is a group of functional brain networks that become more interconnected and a group that becomes less interconnected,' said Dan.
The subcortical-parietal connectivity and the within-limbic connectivity were the most negatively correlated in the ANN, while limbic-insular connectivity was the strongest positive correlation within the APN.
Within the positive connectivity network, ventral attention-somatomotor connectivity had the strongest correlation with age. Frontoparietal-DMN connectivity was the most negatively correlated with age.
Decreased Connectivity, Sociability
Both ANN and APN may contribute to decreased sociability, but it's not yet clear which plays the more dominant role, Dan said.
However, she and her colleagues have some theories. They propose that reduced connectivity between the frontoparietal and DMN regions may be linked to impaired cognition and lower self-esteem, 'thereby resulting in impaired social assertiveness, emotional regulation skills, and reduced sociability.'
Decreased connectivity of these regions could be linked to decreased sociability through impaired executive processing, they noted.
The study illustrates that as we age, 'it may not be just a lack of social contact opportunities that prevents us from forming and maintaining relationships but also an inherent change in the brain's functional wiring,' Dan said.
A mediation analysis showed the effect of age on sociability was fully mediated via both APN and AAN.
'Generally, these statistical results meant that the networks that become more connected, for example APN, as well as less connected, for example, ANN, with age can explain decreased sociability seen across the lifespan,' said Dan.
Dan emphasized that sociability is just one factor related to loneliness — and one that is relatively easy to measure — whereas loneliness itself is a far more complex and deeply subjective experience.
'Intuitively, people with lower sociability scores may be more likely to be lonely, as they may find it harder to maintain relationships. In this sense, increased sociability may be a risk factor for increased loneliness with age.'
Dan said she hopes these preliminary findings will spur more longitudinal research into these relationships and help inform efforts to support healthy aging.
She noted the importance of physicians recognizing that declining sociability may be a natural part of aging. 'Greater emphasis should be placed on community-based health promotion efforts,' she said.
The investigators did not analyze NEO-FFI personality trait variables, so 'we can't draw any conclusions about whether they were related to changes in brain connectivity or sociability,' Dan said.
She also noted that the sample was heavily skewed toward younger participants, which may limit the reliability of the findings for older adults. Additionally, grouping subjects into 5-year age bins may have introduced 'noise' into the statistical models.
Other limitations included an all-European study sample, and collection of sociability data exclusively via self-report, which may be less reliable than more objective measures like social network size.
Interpret With Caution
Commenting for Medscape Medical News , Dirk Scheele, PhD, professor of social neuroscience, Ruhr University Bochum, Bochum, German, said the paper addresses a 'relevant' topic.
'The general question of how social interactions and the desire for social engagement change with age is undoubtedly important, particularly given strong evidence that the risk of social isolation and loneliness increases with advancing age,' he said.
However, the underlying neural mechanisms remain 'surprisingly unclear,' he said. 'For example, no study to date has directly compared the neural substrates of loneliness or social isolation between younger and older adults.'
Although the study 'has the potential to inspire novel research questions,' its findings should be interpreted with 'considerable caution' due to several limitations, he said.
'Most notably, it's an entirely exploratory study without preregistration, and its cross-sectional design prevents conclusions about causal relationships,' he added.
Scheele also noted the 'sociability' construct was derived from a subscale of a questionnaire and 'encompasses multiple facets, such as emotion regulation and social awareness, that may belinked to distinct neural mechanisms.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


San Francisco Chronicle
15 hours ago
- San Francisco Chronicle
Klay Thompson claims being ‘in love' with Megan Thee Stallion has improved his athletic abilities
Former Golden State Warriors player Klay Thompson is deeply in love with Grammy-winning rapper Megan Thee Stallion — and even claims that their budding romance has improved his athletic abilities. Megan documented their recent golf date in Arkansas this week, sharing an over seven-minute-long video recap to Instagram and TikTok in which they take turns teeing off. 'Ever since I've been in love, my golf game's reaped all the benefits,' Thompson notes after tallying up the final score in the clip, which was posted Wednesday, July 23. He also refers to Megan as his 'good luck charm' while on the course. Thompson began doting on the 'Body' rapper long before they began playing, however. Megan began her video by explaining that she let Thompson pick her outfit for the date, having him show off a few options that he purchased for her. She ultimately opted for a white shirt and pink athletic skirt. 'You picked it. You think it's cute?' she asked Thompson while showing off the look on the golf course. 'Mm-hmm, you even got the cute shoes on and the shirt,' he replied. 'I did well, I'm really proud of myself.' The couple made their red carpet debut on July 16, arriving hand in hand to the Pete & Thomas Foundation Gala in New York. Hosted by Megan, the event raised funds for the foundation, which she founded to support underserved communities and honor her late parents. 'This is my first relationship where I've ever been with somebody who's genuinely a nice person, and he makes me genuinely happy,' Megan told Page Six. 'I just never dated somebody like him before and I'm just grateful that he's here by my side and he feels the same way about me.' Megan and Thompson officially went public with their relationship earlier this month, when photos of the two holding hands after dining at Carbone in New York City made rounds online. Thompson spent 13 seasons with the Warriors, helping to lead the Bay Area team to four NBA championships before moving over to the Dallas Mavericks. Megan, a Texas native, wrapped up her 36-city 'Hot Girl Summer' tour last fall. She stopped at Chase Center, home of the Warriors, in June 2024. The previous summer, she performed at Outside Lands in Golden Gate Park.


Medscape
a day ago
- Medscape
Case Reports Describe Itch Relief With Nemolizumab
A recently published case series illustrates how a treatment approved last year for two conditions associated with pruritus could be useful in alleviating itch in patients with a broad variety of other conditions, many of which have a few or no treatment options. In the case series of 70 patients, treatment with nemolizumab — an interleukin (IL)-31 receptor alpha-antagonist approved by the FDA for the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) in 2024 — dramatically reduced itching in a range of additional conditions that cause pruritus. 'Itching causes tremendous suffering,' Jenny Murase, MD, associate clinical professor of dermatology, University of California San Francisco, and one of the authors of the case series, told Medscape Medical News . 'To be unable to sleep and unable to concentrate during the day because the itching is so intense and distracting, to feel like you don't want to live in your own skin — these are incredibly debilitating.' Pruritus, defined as 'an unpleasant sensation that provokes the desire to scratch,' can 'range in intensity from a mild annoyance to an intractable, disabling condition.' Murase, director of Medical Consultative Dermatology and Patch Testing, Palo Alto Medical Foundation, Mountain View, California, said some patients have likened pruritus, which is often accompanied by sensations similar to electric shocks, to being 'tortured.' Many of her patients have tried up to 30 medications, including topical, oral, and injectable agents, receiving minimal if any relief. The multicenter case series examining medical records of 70 patients found nemolizumab dramatically reduced itching in patients with a range of additional conditions that cause pruritus, as measured using the Peak Pruritus Numerical Rating Scale (NRS). The patients described in the report, published in March in the Journal of the American Academy of Dermatology , did not respond to 12 therapies on average. 'The findings of our case review matched my clinical experience using this agent,' Murase said. 'We were excited to uncover the wide range of conditions that responded to it.' In other recently published case reports, authors have described patients with cholestatic pruritus and pruritus of unknown origin who experienced relief from severe pruritus with nemolizumab. In late June, Galderma, the manufacturer of nemolizumab, announced that two clinical trials have been launched to investigate the role of nemolizumab in treating chronic pruritus of unknown origin and systemic sclerosis. Targeting the 'Itch Cytokine' Murase explained that IL-31 is sometimes called the 'itch cytokine.' Because nemolizumab is an IL-31 inhibitor, it works directly on sensory neurons regardless of the underlying cause of the pruritus. In her clinical experience, 'the relief from the itching is extremely fast for the patient after, in some cases, decades of daily itching.' For example, one of her patients with severe pruritus, who was in the case series, did not respond to 30 medications, including JAK inhibitors, IL-4 and IL-13 inhibitors, and neuropathic agents such as pregabalin and gabapentin; was unable to work or sleep; and was forced to quit his job. 'After a single injection of nemolizumab, his symptoms disappeared within 10 days,' Murase said. After 12 days, some mild itching reappeared, 'but his improvements have been largely sustained, and he feels he has his life back for over 8 months now.' Murase and her colleagues were so struck by the potential utility of nemolizumab beyond the two conditions for which it is approved by the FDA that they conducted the case series involving retrospective data collection from medical records of patients who had been treated with nemolizumab for skin diseases associated with pruritus (60 patients) or for burning (10 patients). Conditions affecting these patients included AD, nummular dermatitis, hand dermatitis, dermatographia urticaria, cutaneous mastocytosis, neuropathic itch, subacute prurigo, immunologic eruptions of aging, lymphoma/leukemia, scrotal pruritus, vulvar/anal pruritus, acquired cutaneous brachioradial pruritus, notalgia paresthetica, scabies, post-scabetic Id hypersensitivity, lichen amyloidosis, pernio, and granulomatous dermatitis. Patients experiencing burning had neuropathic skin pain, burning mouth syndrome, neurogenic rosacea, and erythromelalgia. Patients received an initial dose of 60 mg, followed by monthly treatments of 30 or 60 mg, and were followed for an average of 73 days. All 70 patients were considered responders, as defined by a reduction in the NRS score of ≥ 2 and/or a 50% reduction in baseline symptoms, except for one out of two cases of notalgia paresthetica (no response) and acquired cutaneous brachioradial pruritus. Murase noted that the latter patient continued treatment regardless and responded at the 5-month mark after the publication of the case series. Almost all patients (96%) opted to continue taking the medication. 'Many patients started out with an NRS score of 9 or 10, and then their score went to 0 within 2 days. It was truly remarkable,' Murase said in the interview. Investigate Medical Causes Before Prescribing As she and her coauthors noted, Murase expressed a significant concern particularly relevant to patients with no visible cutaneous manifestations such as rash, which could account for their pruritus. In the case series, three patients had leukemia/lymphoma, 20% had renal insufficiency, and 36% had either diabetes or prediabetes. 'All these conditions can predispose patients to have neuropathy and pruritus without a visible rash. Immediately prescribing nemolizumab without thoroughly assessing other potential causes of the itch — especially in lymphoma and leukemia, which can present only with pruritus and no other symptoms — might lead to missed diagnoses of these conditions,' she cautioned. She recounted the story of a male patient in his thirties with dermatographia and no response to an array of previous medications. Murase ordered a hepatitis titer test and a tuberculosis screen, as well as a chest x-ray in preparation to place him on a JAK inhibitor before nemolizumab was available for her to prescribe. She ordered a chest x-ray for an indeterminate QuantiFERON result and diagnosed Hodgkin lymphoma. 'He is alive today because of this,' she commented. 'If I had given him nemolizumab immediately, I would have gotten rid of the only sign that he had lymphoma. The itch reduction is so powerful with the medication that I really want providers to do thorough assessment for malignancy or metabolic conditions before they place their patients on this medication.' Financial Challenges in Prescribing Nemolizumab Murase noted that because nemolizumab is approved only for AD or PN, prescribing it for any other indication is off label, and patients often struggle to get their insurance companies — especially Medicare — to cover the treatment. 'Patients need to have a history of AD, such as a history of rashes in childhood and adulthood, itching, a relapsing and remitting nature, history of hay fever, history of asthma, history of family members with allergies, asthma, and hay fever, to suggest that they could have AD. Or they need to have excoriated lesions for a PN diagnosis.' She noted that these are clinical diagnoses. Murase said that patients in the area where she practices usually have the means to pay out of pocket, and many patients are willing to spend what it takes to obtain the drug because it offers such profound relief. 'I'm hoping that Medicare coverage — and coverage offered by other insurance companies — will improve over time,' she said. Adverse Effects Most patients in the case series experienced no side effects; however, one patient developed facial swelling and erythroderma thought to be caused by discontinuation of abrocitinib. In general, Murase said, nemolizumab has a fairly benign side-effect profile — something she has observed in her own clinical practice. The prescribing information for nemolizumab (Nemluvio) lists the most common adverse reactions (affecting 1% or more of patients) as headache, AD, eczema, and nummular eczema with PN and headache (including migraine), arthralgia, urticaria, and myalgia with AD. A 2025 review of cutaneous adverse events following administration of nemolizumab found an increased incidence of psoriasiform eruptions, AD exacerbations, bullous pemphigoid, nonspecific drug-induced eruptions, fungal infections, urticaria, acne, and contact dermatitis in patients receiving nemolizumab and overall cutaneous adverse events in about 30%-50% of patients. A review and meta-analysis of three studies of nemolizumab for PN encompassing almost 500 patients found no difference between nemolizumab and placebo in the rates of adverse events or serious adverse events. Transforming the Landscape Commenting for Medscape Medical News , Adam Friedman, MD, professor and chair of dermatology, George Washington University, Washington, DC, said that 'pruritus is not just a symptom; it's a disease in and of itself and one that deserves targeted therapy.' The case series by Murase and colleagues, he said, 'reinforces what we've seen clinically, which is that nemolizumab can provide rapid and profound relief for patients with a wide range of underlying conditions, including those with inflammatory and more difficult-to-manage idiopathic itch.' Nemolizumab has 'transformed the landscape' of PN, an on-label use, Friedman said. He has also prescribed it for itch associated with systemic lupus erythematosus, pruritus associated with various cancer treatments, idiopathic pruritus in older adult patients, and even delusions of parasitosis, 'where traditional antipruritics fall short.' Friedman, also director of translational research and director of supportive oncodermatology at George Washington University, noted that his clinical experience accords with the findings of the case series that nemolizumab 'tends to disappoint' in centrally mediated conditions such as notalgia paresthetica and brachioradial pruritus. And he echoed Murase's caveat that 'diagnostic rigor is critical.' He added that itch is 'very personal,' so clinicians should 'tailor therapy, set expectations, and reassess frequently.' Also commenting for Medscape Medical News , Lauren Ploch, MD, MEd, of Georgia Dermatology & Skin Cancer Center in Augusta and Aiken, South Carolina, agreed that the workup of patients without primary skin lesions should include ruling out medical causes such as renal disease and malignancies, and that patients should be monitored — although some of the newer medications 'do not require strict lab monitoring.' Murase added that nemolizumab can be useful in every medical specialty that treats patients with pruritus. 'For example, vulvar pruritus drives patients crazy. I heard about one patient who was literally sitting on ice throughout the day because her symptoms of itching and burning were so life-altering. Within a few days of treatment [with nemolizumab], her symptoms had abated.' In addition, she said, it is also an option for urologists treating scrotal itch, 'which can be horrific even though there is very little to see on the skin. And one of the most debilitating symptoms of chronic kidney disease is pruritus, which has been shown to sap quality of life in these patients more than other symptoms. Now, nephrologists have something to offer these patients.' Murase and her colleagues are in the process of publishing a post hoc analysis of the rapidity of itch relief with nemolizumab in patients with pruritus. The study received no funding. Murase reported being on the speakers board for Galderma, UCB, Leo Pharma, Eli Lilly, AbbVie, and Sanofi-Regeneron; serving on advisory boards for UCB, Galderma, Arcutis, Eli Lilly, Leo Pharma, Sanofi-Regeneron, and Bristol Myers Squibb; and providing dermatologic consulting services for UCB, Apogee Therapeutics, Galderma, AbbVie, Attovia, Sanofi-Regeneron, and UpToDate. Friedman reported being a speaker, investigator, and consultant for Galderma. Ploch reported having no relevant financial relationships.


Medscape
a day ago
- Medscape
Transoral Ultrasound Outperforms MRI in Cancer Detection
TOPLINE: A trial including 162 patients showed that surgeon-performed transoral/transcervical ultrasonography (USG) achieved a diagnostic accuracy of 86%, outperforming clinical examination and MRI (68% and 76%, respectively), in detecting oropharyngeal squamous cell carcinoma (OPSCC). METHODOLOGY: This prospective, multicentre diagnostic clinical trial included 162 participants with suspected OPSCC (median age, 63 years; 35% women) in Denmark from 2023 to 2024. After clinical examination, participants underwent transoral and transcervical USG performed by surgeons, followed by blinded cross-sectional MRI evaluation. Transoral USG involves using small high-frequency ultrasound probes placed directly onto the oropharyngeal mucosa, which produce higher-resolution images than traditional cross-sectional imaging. Researchers compared accuracies of detecting OPSCC between clinical examination, USG, and MRI, with final histopathologic results and T staging being used as reference standards. TAKEAWAY: A total of 65% of participants were diagnosed with oropharyngeal tumours and 35% were diagnosed without those. USG achieved significantly higher overall accuracy (86%) than clinical examination (68%; odds ratio [OR], 0.31; 95% CI, 0.18-0.52) and MRI (76%; OR, 0.48; 95% CI, 0.28-0.82) in diagnosing OPSCC. Among patients without tumours, USG demonstrated superior specificity than clinical examination and MRI (79% vs 41% and 46%, respectively), while maintaining comparable sensitivity (90% vs 82% and 92%, respectively). Grouping of surgeons on the basis of their experience as 0-10, 10-20, and ≥ 20 cases yielded diagnostic accuracies of 80%, 79%, and 87%, respectively. Surgeons rated higher image quality in 45% vs 17% of OPSCC cases with transoral vs transcervical USG. IN PRACTICE: "Transoral ultrasonography was well tolerated and can be performed as an extension of the clinical examination to improve diagnostic evaluation and to inform biopsy procedures," the authors wrote. "Transoral ultrasonography may have a role in identifying early-stage OPSCCs and improving patient selection for transoral robotic surgery," they added. SOURCE: This study was led by Martin Garset-Zamani, MD, PhD, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark. It was published online on July 17, 2025, in JAMA Otolaryngology-Head & Neck Surgery. LIMITATIONS: This study was conducted in tertiary centres with specialised head and neck surgeons experienced in USG, which may have limited generalisability. Considering inconclusive cases as positive may have led to overdiagnosis, especially in patients with asymmetric tonsils. Additional limitations included the absence of a true reference standard for T staging. DISCLOSURES: This study was supported by a grant from the Novo Nordisk Foundation. One author reported having a patent pending for a 3D USG imaging device at Rigshospitalet. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.